Venoms are a proven therapeutic resource with several drugs in development for cancer therapeutics such as antimetastics and tumour cell apoptosis. Snake venoms are rich source of new oncology tools including disintegrins, L-amino-acid oxidase and a wealth of signalling peptides. These targeted arrays contain pure venom fractions from 12, 24, 48 or 96 species optimised for identification of novel tools. Each array contains characterised venoms active in analgesic pathways from the literature to act as positive controls. The control venoms for T-VDA Oncol include Agkistrodon contortrix (Southern copperhead) where the disintegrin Contortrostatin was discovered [1]; Deinagkistrodon acutus (hundred pace pit viper) which contains an L-amino acid oxidase enzyme that induces apoptosis in HeLa cancer cells [2]; and Leiurus quinquestriatus (death stalker scorpion) venom which contains small neurotoxic peptides that block chloride channels and can label gliomas [3]. The other venom fractions making up the library have been specially selected by our drug discovery scientists to maximise novel hit potential.

• Venoms are supplied lyophilised in Echo qualified acoustic source plates (Labcyte Inc) and are useable on any SBS footprint liquid handling device or by hand.

• 384-well format has 200ng venom fraction per well, suggested dilution 20µl as hit fractions are typically active at 5µg/ml and below.

• 1536-well format also available.